<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928849</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00047194</org_study_id>
    <secondary_id>PT110575</secondary_id>
    <nct_id>NCT01928849</nct_id>
  </id_info>
  <brief_title>Valproic Acid for the Prevention of Post-Amputation Pain</brief_title>
  <official_title>Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are, to test the effectiveness of Valproic Acid (VPA) in the
      prevention of chronic neuropathic and post-amputation pain, as well as to further define the
      underlying inflammatory and epigenetic mechanisms that lead to the development of such
      chronic pain.

      HYPOTHESES AND QUESTIONS

      Hypothesis 1: The use of oral valproic acid in combination with regional anesthesia in
      surgical limb-injury patients will decrease the incidence of chronic nerve injury and
      post-amputation pain.

      Goal 1: In a blinded, randomized placebo-controlled, multi-center clinical trial,
      investigators will determine if oral VPA added to regional anesthesia and standard
      perioperative management will reduce the incidence of nerve injury and post-amputation pain
      when compared with regional anesthesia alone.

      Hypothesis 2: The transition from acute to chronic pain is mediated via epigenetic mechanisms
      (differential DNA methylation) in genes involved in nociception.

      Goal 2: Investigators will analyze the DNA methylation patterns of patients with different
      types of neuropathic and post-amputation pain and determine if they are altered by VPA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH DESIGN

      This study will be a prospective, randomized, double-blinded, placebo-controlled trial to
      test the efficacy of valproic acid (VPA) in reducing the incidence of chronic neuropathic and
      post-amputation pain following amputation, stump revision, and surgery for limb injury with
      neurologic damage. Patients randomized to the &quot;Control arm&quot; of the trial, will receive
      standard regional anesthesia catheters (either peripheral nerve or epidural catheter),
      anesthetic management and a placebo. Patients randomized to the &quot;Intervention arm&quot; of the
      trial will receive standard regional anesthesia catheters (either peripheral nerve or
      epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then
      three times per day for either 6 days post-operatively or until the time of discharge.

      METHODOLOGY

      The enrollment goal for the study (from all sites) will be 224 patients. Subjects will be
      recruited from the surgical clinics and the anesthesia pre-operative clinic. Outcomes for
      patients in the intervention arm will be compared with those managed with the current
      institutional standards of care including regional anesthesia catheter infusions. The study
      team anticipates a 10% drop-out rate at 3 months secondary to death and loss to follow up.
      Thus 202 evaluable patients (101 patients in each arm) at 3 months after surgery will be
      included in this study.

      After screening and enrollment, the study medication (VPA or placebo) will be administered.
      Research blood samples will be collected preoperatively, postoperatively (at the completion
      of study drug administration, and at the Amputation Clinic follow-up for expression analysis.
      The third and final blood draw will be taken at the 3 month follow up. If patient is
      unavailable the research team will make accommodations to collect blood sample at the 6 month
      follow up or at a time of maximal patient convenience, not to exceed 18 months from study
      enrollment. All samples will be de-identified and subsequently studied in our laboratory and
      core facilities at Duke. Study specific questionnaires will be administered during the
      hospital stay, at 1 month (via mail), at 3 months (in clinic) and at 6 months (in clinic when
      possible).

      RANDOMIZATION AND TREATMENT

      Randomization will be stratified by site and by surgical etiology. At the time of enrollment,
      subjects will be assigned to one of three surgical categories on the randomization assignment
      log: amputation, stump revision, or surgery for limb injury with neurologic damage. Prior to
      surgery, the Investigational Drug Pharmacist will dispense the study medication in liquid
      form and the container will be labeled &quot;study drug&quot; with no indication of the liquid
      contents. The pharmacist will be the only person aware of the treatment allocation. At the
      end of the trial, once endpoint adjudication has been completed for all study subjects, the
      study data and treatment allocation will be un-blinded. Initial drug administration will be
      performed prior to induction of anesthesia on the day of surgery. Subsequent doses will be
      administered at the bedside by the ICU or floor nurse depending on patient location.
      Participants will complete study drug administration unless they withdraw their consent or
      either their treating physician or the principal investigator believes it would be dangerous
      to continue valproic acid. If the subject withdraws during the administration of VPA, they
      will continue with their current medical regimen without alteration.

      DATA ANALYSIS PLAN

      The primary endpoint is the incidence of chronic pain at the 3 months or time of final
      adjudication evaluation point, and the chronic pain will be defined as an S-LANSS average
      pain score of 3 points or greater. Secondary endpoints will include the numeric scores from
      forms BPI, S-LANSS, and DVPRS and the change in these scores from baseline to 3 months or
      time of final adjudication, as well as the incidence of neuropathic limb or post-amputation
      pain at enrollment and 3 months or time of final adjudication. Frequency and percentage of
      the categorical variables in above endpoints will be reported by treatment arm and by
      assessed time. Mean, standard deviation and range of the mean scales of the above forms, as
      well as the changes of mean scales from baseline will be computed by arm and by assessed
      time. Two-sample chi-square tests will be used to assess the treatment difference of the
      primary endpoint and post-amputation pain (or neuropathic pain) at each time. Logistic
      regression will be applied to investigate the treatment difference on the primary endpoint
      and post-amputation pain by adjusting for potential prognostic variables including baseline
      pain level, study site, type of surgery, diabetes, and intervening therapies. Similar
      analyses will be carried out in study sub-groups of site, surgery type, and diabetic status.
      Two sample t-tests will be used to assess treatment difference in changes of mean scales from
      baseline. In addition, linear regression will be used to assess the treatment difference on
      changes of mean scales from baseline by adjusting for covariants. P values of less than 0.05
      will be considered to indicate statistical significance. Intent-to-treat analysis will be
      performed. Sensitivity analyses will also be carried out by excluding patients who drop out
      before 3 month post-surgery. If the dropout rate is larger than 10% and if there is evidence
      that the missing mechanism is not MCAR (missing completely at random) but MAR (missing at
      random), multiple imputation will be conducted. RASS will be used during hospitalization to
      define any changes in sedation between study groups during drug administration.

      Analysis of clinical study data will be carried out with a de-identified download from
      REDCap. All of these data shared with the Duke Center for Human Genetics (CHG) will be fully
      stripped of all 18 Health Insurance Portability and Accountability Act (HIPAA)identifiers
      (ID). Private health information of study participants will be respected and all data
      analysis will be done in blinded fashion, such that individuals will not be identifiable from
      the final analysis dataset. Each patient will be allocated a study ID number when they sign a
      consent form, and thereafter will be referred to by that number. Investigators will have
      secure password protected access to REDCap in order to enter data. The dataset and
      biorepository will be fully de-identified once the dataset is complete and locked.

      Research blood samples are tracked and stored within our existing Laboratory Inventory
      Management System. All specimens are identified by barcode and are not identifiable except
      via a coding table held securely at Duke University Medical Center (DUMC), Durham Veterans
      Administration Medical Center (VAMC) and Walter Reed National Military Medical Center
      (WRNMMC) respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 26, 2017</completion_date>
  <primary_completion_date type="Actual">September 26, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Chronic Post-amputation Pain</measure>
    <time_frame>3 months or time of final adjudication assessment, up to 6 months</time_frame>
    <description>The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pain Sub-types</measure>
    <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
    <description>The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Analgesic Requirement</measure>
    <time_frame>Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)</time_frame>
    <description>The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Short Form Score</measure>
    <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
    <description>The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (S-LANSS)</measure>
    <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
    <description>The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defense and Veterans Pain Rating Scale (DVPRS) Score</measure>
    <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
    <description>The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Richmond Agitation-Sedation Scale (RASS)</measure>
    <time_frame>during hospitalization (0-24 hours and 24-48 hours post-surgery)</time_frame>
    <description>The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Observation of Epigenetic Alterations That Occur in the Transition From Acute to Chronic Pain.</measure>
    <time_frame>Changes between enrollment, end of study drug and 3 months or time of final adjudication</time_frame>
    <description>Epigenetic analysis (DNA methylation) will be correlated with pain sub-type and use of Valproic Acid.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Pain, Phantom</condition>
  <condition>Pain, Neuropathic</condition>
  <arm_group>
    <arm_group_label>Cherry syrup</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cherry Syrup: Patients randomized to the &quot;Control arm&quot; of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>&quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
    <arm_group_label>Valproic Acid</arm_group_label>
    <other_name>Depacon, Depakene, Depakote, Stavzor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cherry Syrup</intervention_name>
    <description>Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
    <arm_group_label>Cherry syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female active duty military personnel or veterans, age 18 years and older.

          -  Patient is scheduled to undergo amputation, stump revision, or surgery for a limb
             injury with neurologic damage.

          -  Patient able to provide written informed consent prior to any study procedures.

        Exclusion Criteria:

          -  Severe Traumatic Brain Injury (Diagnosis of traumatic brain injury resulting in
             documented, permanent or prolonged cognitive deficits that would preclude
             participation in the study)

          -  Significant cognitive deficits or dementia of any cause as noted in Computerized
             Patient Record System(CPRS).

          -  Patient has a designated Legally Authorized Representative

          -  Substantial hearing loss without alternative means of communication.

          -  Patient has documented spinal cord injury with permanent or persistent deficits

          -  Patient is under age 18 or a legal Minor

          -  Current pregnancy or lactation

          -  Cirrhosis with evidence of decompensation: coagulopathy International Normalized Ratio
             (INR) &gt;1.3, thrombocytopenia with platelets &lt;100,000, ascites or hepatic
             encephalopathy

          -  Therapy with valproic acid or other valproates, coumadin, chlorpromazine and
             olanzapine at the time of surgery and study drug administration

          -  Current diagnosis of seizure disorder requiring anti-epileptic medication

          -  Current therapy with tricyclic antidepressants (eg: amitriptyline, nortriptyline,
             imipramine, desipramine) at doses greater than 50mg/day

          -  Currently taking zidovudine

          -  Current diagnosis of malaria requiring anti-malaria medication (such as mefloquine and
             chloroquine)

          -  Currently taking monoamine oxide inhibitors (MAOI)

          -  Allergy to valproates or valproic acid

          -  Contraindication to, or refusal of, regional anesthesia catheter

          -  BMI &gt; 50
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E Buchheit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD009183. doi: 10.1002/14651858.CD009183.pub2. Review.</citation>
    <PMID>21975791</PMID>
  </reference>
  <reference>
    <citation>Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, Kim JM, Park DK, Kun Lee S, Kim M, Roh JK. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis. 2007 May;26(2):464-72. Epub 2007 Feb 23.</citation>
    <PMID>17398106</PMID>
  </reference>
  <reference>
    <citation>Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem. 2003 Jul 25;278(30):27586-92. Epub 2003 May 14.</citation>
    <PMID>12748177</PMID>
  </reference>
  <reference>
    <citation>Zhang Z, Cai YQ, Zou F, Bie B, Pan ZZ. Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med. 2011 Oct 9;17(11):1448-55. doi: 10.1038/nm.2442.</citation>
    <PMID>21983856</PMID>
  </reference>
  <reference>
    <citation>Reiber GE, McFarland LV, Hubbard S, Maynard C, Blough DK, Gambel JM, Smith DG. Servicemembers and veterans with major traumatic limb loss from Vietnam war and OIF/OEF conflicts: survey methods, participants, and summary findings. J Rehabil Res Dev. 2010;47(4):275-97.</citation>
    <PMID>20803399</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>September 26, 2018</results_first_submitted>
  <results_first_submitted_qc>September 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2018</results_first_posted>
  <last_update_submitted>November 28, 2018</last_update_submitted>
  <last_update_submitted_qc>November 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amputation</keyword>
  <keyword>Post-amputation Pain</keyword>
  <keyword>Neuropathic pain</keyword>
  <keyword>Valproic Acid</keyword>
  <keyword>Anesthesia, Conduction</keyword>
  <keyword>Neuralgia, stump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Phantom Limb</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT01928849/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cherry Syrup</title>
          <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
        </group>
        <group group_id="P2">
          <title>Valproic Acid</title>
          <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cherry Syrup</title>
          <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
        </group>
        <group group_id="B2">
          <title>Valproic Acid</title>
          <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="16.6"/>
                    <measurement group_id="B2" value="51.1" spread="18.2"/>
                    <measurement group_id="B3" value="50.7" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Chronic Post-amputation Pain</title>
        <description>The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3.</description>
        <time_frame>3 months or time of final adjudication assessment, up to 6 months</time_frame>
        <population>Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chronic Post-amputation Pain</title>
          <description>The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3.</description>
          <population>Participants who completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Univariable Logistic regression</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pain Sub-types</title>
        <description>The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point.</description>
        <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
        <population>Participants who completed the study. For the cherry syrup (placebo) arm, only 50 participants completed the full adjudication process necessary to determine phantom pain sub-type.</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pain Sub-types</title>
          <description>The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point.</description>
          <population>Participants who completed the study. For the cherry syrup (placebo) arm, only 50 participants completed the full adjudication process necessary to determine phantom pain sub-type.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Residual limb pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phantom limb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of rate of residual limb pain between treatment groups</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of rate of Phantom limb pain between treatment groups</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect on Analgesic Requirement</title>
        <description>The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery.</description>
        <time_frame>Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)</time_frame>
        <population>Patients who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect on Analgesic Requirement</title>
          <description>The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery.</description>
          <population>Patients who completed the study</population>
          <units>morphine milligram equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postoperative hours 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="20" upper_limit="89"/>
                    <measurement group_id="O2" value="33" lower_limit="20" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative hours 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="24" upper_limit="159"/>
                    <measurement group_id="O2" value="45" lower_limit="20" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of opioid consumption postoperative hours 0-24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of opioid consumption postoperative hours 24-48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory (BPI) Short Form Score</title>
        <description>The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference.</description>
        <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
        <population>Those completing questionnaires at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Short Form Score</title>
          <description>The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference.</description>
          <population>Those completing questionnaires at both time points</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPI Average Pain Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-3" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI interference question sum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15" lower_limit="-33" upper_limit="-4"/>
                    <measurement group_id="O2" value="-7" lower_limit="-31" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of BPI average pain score</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of BPI Interference question sum</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (S-LANSS)</title>
        <description>The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain.</description>
        <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
        <population>Patients who completed questionnaire at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (S-LANSS)</title>
          <description>The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain.</description>
          <population>Patients who completed questionnaire at both time points</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-5" upper_limit="-1"/>
                    <measurement group_id="O2" value="-2" lower_limit="-5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Defense and Veterans Pain Rating Scale (DVPRS) Score</title>
        <description>The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations.</description>
        <time_frame>Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
        <population>Patients who completed questionnaires at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Defense and Veterans Pain Rating Scale (DVPRS) Score</title>
          <description>The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations.</description>
          <population>Patients who completed questionnaires at both time points</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DVPRS numeric pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-3" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-3.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DVPRS Supplemental Question Sum</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-18" upper_limit="-1"/>
                    <measurement group_id="O2" value="-4.5" lower_limit="-17" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of DVPRS numeric pain score</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of DVPRS supplemental question sum</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Richmond Agitation-Sedation Scale (RASS)</title>
        <description>The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)).</description>
        <time_frame>during hospitalization (0-24 hours and 24-48 hours post-surgery)</time_frame>
        <population>Participants who completed the RASS assessment on post-op day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Cherry Syrup</title>
            <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
          </group>
          <group group_id="O2">
            <title>Valproic Acid</title>
            <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Richmond Agitation-Sedation Scale (RASS)</title>
          <description>The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)).</description>
          <population>Participants who completed the RASS assessment on post-op day 1.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-op hours 0-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-op hours 24-48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of RASS postoperative hours 0-24</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of RASS postoperative hours 24-48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Observation of Epigenetic Alterations That Occur in the Transition From Acute to Chronic Pain.</title>
        <description>Epigenetic analysis (DNA methylation) will be correlated with pain sub-type and use of Valproic Acid.</description>
        <time_frame>Changes between enrollment, end of study drug and 3 months or time of final adjudication</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Severe adverse events were collected from surgery to 3 months or time of final adjudication assessment (up to 6 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cherry Syrup</title>
          <description>Cherry Syrup: Patients randomized to the &quot;Control arm” of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo.
Cherry Syrup: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.</description>
        </group>
        <group group_id="E2">
          <title>Valproic Acid</title>
          <description>&quot;Intervention arm&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid.
Valproic Acid: &quot;Intervention&quot; patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and infestations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Buchheit, MD Division Chief, Pain Medicine</name_or_title>
      <organization>Duke University Department of Anesthesiology</organization>
      <phone>9196811924</phone>
      <email>Thomas.Buchheit@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

